Evidence map›Paper›PMID 41569442›Full record

ArticleBreast cancer research and treatment2026

Molecular and socioeconomic characteristics of inflammatory breast cancer in the Carolina Breast Cancer Study.

Qichen Wang, Sarah C Van Alsten, Xiaojia Ji, Esraa Salim, Nicole Salazar, John E Scott, Xiaohe Yang, Rob U Onyenwoke, Melissa A Troester, Kevin P Williams

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qichen WangDepartment of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. qiw@unc.edu.ORCID http://orcid.org/0009-0002-1183-9939
Sarah C Van AlstenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Xiaojia JiBiomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, 27707, USA.
Esraa SalimBiomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, 27707, USA.
Nicole SalazarJulius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC, 27707, USA.
John E ScottBiomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, 27707, USA.
Xiaohe YangJulius L. Chambers Biomedical/Biotechnology Research Institute, North Carolina Central University, Durham, NC, 27707, USA.
Rob U OnyenwokeBiomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, 27707, USA.
Melissa A Troester *Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID http://orcid.org/0000-0001-9506-6624
Kevin P Williams *Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID http://orcid.org/0000-0002-6930-4630

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN CARLISLE CALHOUN · 1992 to 2026
$59.3M
Understanding Perceptions of HIV Risk, PrEP, and PrEP use among African American Women Attending an HBCUU54MD012392 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI MICHELER Ricardo RICHARDSON · 2017 to 2026
$38.1M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
P53, DNA Repair Imbalance, and Immune Response in Breast Cancer Mortality DisparitiesR01CA253450 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY, Melissa A. Troester · 2021 to 2026
$3.6M
Addressing the Biology of Health Disparities by Targeting Geographical Ancestry-driven Variants of ImmunityR01MD017405 · NIMHD · NORTH CAROLINA CENTRAL UNIVERSITY · PI KIMBRO, KEVIN SEAN, NAVARRO, HERNAN A · 2021 to 2025
$3.4M
Breast Cancer Research Foundation HEI-23-003National Cancer Institute of the National Institutes of Health P30CA016086National Cancer Institute Specialized Program of Research Excellence (SPORE) in Breast Cancer NIH/NCI P50-CA058223NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA058223NCI NIH HHS R01 CA253450NCI NIH HHS R01CA253450NCI NIH HHS T32 CA057726NIMHD NIH HHS R01 MD017405NIMHD NIH HHS RCMI U54MD012392 and R01MD017405NIMHD NIH HHS U54 MD012392Susan G. Komen OGUNC1202, TREND21686258, SAC210102UNC Lineberger Comprehensive Cancer Center; University Cancer Research Fund of North Carolina OG22873776U.S. Department of Defense HT94252310235
6 · The paper itself

Abstract

purposeInflammatory breast cancer (IBC) has been hypothesized to represent a distinct molecular subtype. However, few IBC-specific gene expression patterns have been identified, and previous genomic studies of IBC have been small with limited information on social determinants.

methodsWe identified 153 IBC cases in the Carolina Breast Cancer Study (total N = 4,739). RNA expression was measured on the NanoString platform (N = 74 IBC, 2,696 non-IBC) and used to determine molecular subtypes, including PAM50, immune, homologous recombination deficiency (HRD), and P53 status. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) of associations between IBC and patient demographic, molecular, and social characteristics using logistic regression, and compared differences in gene expression using ANOVA.

resultsWomen with IBC were associated with Black and under 50 compared to non-IBC. IBC was associated with rural address (OR = 1.53) and poverty (OR = 1.61). Molecularly, IBC was associated with HER2-enriched (OR = 6.14), Luminal B (OR = 2.90), P53 Mutant-like (OR = 1.79), and high HRD (OR = 1.90). Neither adiposity nor immune subtype was significantly associated with IBC. Only six of 219 genes measured were significantly differentially expressed between IBC and non-IBC, including HER2-related (ERBB2, FGFR4, GRB7) and P53-related genes (BTG2, LOC400043, MAP2K4).

conclusionAlthough not associated with immune subtypes, IBC showed differences in HER2 and P53 pathways. The association of IBC with rurality and poverty underscores the importance of health care access for timely diagnosis and treatment of IBC.

Indexed as

Inflammatory Breast NeoplasmsAdultAgedBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNorth CarolinaOdds RatioSocioeconomic Disparities in HealthSocioeconomic FactorsTumor Suppressor Protein p53Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesTumor Suppressor Protein p53Carolina Breast Cancer StudyInflammatory Breast CancerPAM50Socioeconomic Status

Identifiers

PMID41569442
PMCPMC12827424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.